Trehalose - Bioblast Pharma

Drug Profile

Trehalose - Bioblast Pharma

Alternative Names: Cabaletta; Trehalose dihydrate

Latest Information Update: 01 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioblast Pharma
  • Class Disaccharides; Glucans; Small molecules
  • Mechanism of Action Autophagy stimulants; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration; Oculopharyngeal muscular dystrophy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Oculopharyngeal muscular dystrophy
  • Phase II Spinocerebellar degeneration
  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2017 Bioblast Pharma completes a phase III trial in Oculopharyngeal muscular dystrophy (In the elderly, In adults) in Israel (IV) (NCT02328482)
  • 11 Sep 2017 Discontinued - Preclinical for Spinal muscular atrophy in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top